

of the CRP levels after treatment, there is a strong possibility that CRP is a marker of exacerbation of COPD.

Recommendation

We suggest that, in exacerbation of COPD, CRP estimation provides a useful and inexpensive early marker of the exacerbation and provides a useful guide to assess the efficacy of treatment

References

1. John J, Reilly JR, Edwin K, and Silverman SD. Chronic obstructive pulmonary disease. In: Kasper DL, Fauci AS, Longo DL, Braunwald E, Hauser SL, and Jameson JL, Harrison's Principles of Internal Medicine 16th ed. New York, McGrawHill, 2005; p. 1547-1554.
2. Senior RM, and Shapiro SD. Chronic obstructive pulmonary disease: Epidemiology, pathophysiology, and pathogenesis. In: Fishman's Pulmonary Diseases and Disorders, 3d ed. Fishman AD et al (eds). New York, McGraw-Hill, 1998; p. 659-681.
3. Barnes PJ. Chronic obstructive pulmonary disease. *N Eng J Med*, 2000; 343: 269-280.
4. ATS/ERS. Skeletal muscle dysfunction in chronic obstructive pulmonary disease. A statement of the American Thoracic Society and European Respiratory Society. *Am J Respir Crit Care Med*, 1999; 159: S1-40.
5. Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. *Thorax*, 2004; 59(7): 574-580.
6. Vernooy JH, Küçükaycan M, Jacobs JA, Chavannes NH, Buurman WA, Dentener MA, et al. Local and systemic inflammation in patients with Chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*, 2002; 166(9): 1218-1224.
7. Noguera A, Busquets X, Saucedo J, Villaverde JM, MacNee W, Agustí AG. Expression of adhesion molecules and G proteins in circulating neutrophils in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*, 1998; 158, 1664-1668.
8. Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. *Thorax*, 2004; 59(7): 574-580.
9. Kasper DL, Fauci AS, Longo DL, Braunwald E, Hauser SL, Jameson JL. Harrison's Manual of Medicine 16th ed. New York, McGrawHill, 2005; p. 675-678.
10. Glass S, Hayward C, and Govan JRW. Serum CRP in assessment of pulmonary exacerbation and microbial therapy in cystic fibrosis. *Paediatr*, 1988; 113: 76-79.
11. Raynor RH, Wiseman MS, Cordon SM, Hillar EJ, Shale DJ. Inflammatory markers in cystic fibrosis. *Respir Med*, 1991; 85: 139-145.
12. Dev D, Wallance E, Sankaran J, and Cuniffe J. Value of C-reactive protein measurement in exacerbation of COPD. *Respiratory medicine*, 1998; 92: 664-667.
13. Pepys MB. C-reactive protein: 50 years on. *Lancet*, 1981; 1: 653-657.
14. Peltola HO. C-reactive protein for rapid monitoring of infection of the CNS. *Lancet*, 1982; I: 980-982.
15. Shaw AC. Serum CRP and neopterin concentrations in patients with viral or bacterial infection. *J Clin Pathol*, 1991; 44: 596-599.
16. Nel AE, Strachan AF, Welka HE, and de Beer FC. Acute phase responses in bronchiectasis and bronchial carcinoma. *Respiration*, 1984; 45:406-410.
17. Sodeman TM, and Colmer J. Microbiology of the respiratory tract. *Lab Med*, 1983; 14(2): 96-102.
18. Woods DE. Bacterial colonization of the respiratory tract: clinical significance. In: Respiratory infections: Diagnosis and Management, 2nd ed. New York, Raven Press, 1988.

Correspondence to: Dr. Methaq A.M. Hussein,
E-mail: m.hilalali@yahoo.com

Received: 16th Nov. 2008, Accepted: 29th Sept. 2010.